USA: Research Lonza, Allcells Team Up for Commercialisation of Hematopoietic Primary Cells
The partnership aims to manufacture and globally commercialise an extensive range of hematopoietic primary cells. By leveraging Allcells customisation expertise, speed and flexibility to manufacture hematopoietic cells of superior viability and quality, and with Lonza's extensive reach, it will improve the availability of highly purified cells from different tissue sources to enhance a variety of research needs.
Maryland/USA – Lonza and Allcells have recently entered into a private label partnership for the manufacture and global commercialisation of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of high-quality cells to boost their scientific research.
Under the new agreement, the entire Allcells research portfolio of products will bear the Lonza branding and will allow scientists on a global scale to further their research across an array of applications, including drug discovery, toxicity testing, cell therapy and personalised medicine.
Hematopoietic primary cells play a vital role in advancing in vitro research as they closely reflect in vivo morphology, metabolism and growth characteristics. However, obtaining those cells requires researchers to find a variety of donors and perform a series of tedious cell isolations.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45748316)